The Combination of Age, International Standardized Ratio, Albumin and γ-Glutamyl Transpeptidase (AIAG), Tumor Size and Alpha Fetoprotein (AFP) Stage as the Prognostic Model for Hepatitis B-Related Hepatocellular Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Petrizzo A, Tagliamonte M, et al. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013;59(4):897–903. doi:10.1016/j.jhep.2013.05.031
   PubMed Web of Science ®Google Scholar
• Kabbach G, Assi HA, Bolotin G, et al. Hepatobiliary tumors: update on diagnosis and management. J Clin Transl Hepatol. 2015;3:169–181.
   PubMedGoogle Scholar
• Jafri W, Kamran M. Hepatocellular carcinoma in Asia: a challenging situation. Euroasian J Hepatogastroenterol. 2019;9(1):27–33. doi:10.5005/jp-journals-10018-1292
   PubMedGoogle Scholar
• Geh D, Anstee QM, Reeves HL. NAFLD-associated HCC: progress and opportunities. J Hepatocell Carcinoma. 2021;8:223–239. doi:10.2147/JHC.S272213
   PubMed Web of Science ®Google Scholar
• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–1183. doi:10.1001/jama.2020.2298
   PubMed Web of Science ®Google Scholar
• Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood). 2020;245(2):96–108. doi:10.1177/1535370219898141
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Shindoh J, Margonis GA, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg. 2017;152(3):e165059. doi:10.1001/jamasurg.2016.5059
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng C, Zhou H, et al. Comparison of Modified Child-Pugh (MCP), Albumin-bilirubin (ALBI), and Child-Pugh (CP) score for predicting of survival in hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization. Bull Cancer. 2021:S0007–S4551. PMID: 34247763. doi:10.1016/j.bulcan.2021.04.017
   Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61–74. PMID: 20175034. doi:10.1055/s-0030-1247133
   PubMed Web of Science ®Google Scholar
• Dong M, Wu J, Yu X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int. 2018;38(9):1562–1570. doi:10.1111/liv.13688
   PubMed Web of Science ®Google Scholar
• Ho SY, Wang LC, Hsu CY, et al. Metavir fibrosis stage in hepatitis C-related hepatocellular carcinoma and association with noninvasive liver reserve models. J Gastrointest Surg. 2020;24(8):1860–1862. doi:10.1007/s11605-020-04627-1
   PubMed Web of Science ®Google Scholar
• Marasco G, Colecchia A, Silva G, et al. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol. 2020;26(24):3326–3343. doi:10.3748/wjg.v26.i24.3326
   PubMed Web of Science ®Google Scholar
• Wu SD, Ni YJ, Liu LL, et al. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int. 2012;6(1):360–368. doi:10.1007/s12072-011-9328-1
   PubMed Web of Science ®Google Scholar
• Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019;20(6):1358. doi:10.3390/ijms20061358
   PubMed Web of Science ®Google Scholar
• Zakaria HM, Mohamed A, Omar H, et al. Alpha-fetoprotein level to total tumor volume as a predictor of hepatocellular carcinoma recurrence after resection. A retrospective cohort study. Ann Med Surg. 2020;54:109–113. doi:10.1016/j.amsu.2020.04.014
   PubMed Web of Science ®Google Scholar
• Zakaria HM, Macshut M, Gaballa NK, et al. Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study. Ann Med Surg. 2020;54:47–53. doi:10.1016/j.amsu.2020.04.001
   PubMed Web of Science ®Google Scholar
• Liang L, Wang MD, Zhang YM, et al. Association of postoperative biomarker response with recurrence and survival in patients with hepatocellular carcinoma and high alpha-fetoprotein expressions (>400 ng/mL). J Hepatocell Carcinoma. 2021;8:103–118. doi:10.2147/JHC.S289840
   PubMed Web of Science ®Google Scholar
• Liu H, Yang Y, Chen C, et al. Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum p value method: a large retrospective study. World J Surg Oncol. 2020;18(1):185. doi:10.1186/s12957-020-01963-z
   PubMed Web of Science ®Google Scholar
• Kim MN, Hwang SG, Kim BK, et al. Liver cirrhosis, not antiviral therapy, predicts clinical outcome in cohorts with heterogeneous hepatitis B viral status. Gut Liver. 2019;13(2):197–205. doi:10.5009/gnl18204
   PubMed Web of Science ®Google Scholar
• Adhoute X, Penaranda G, Bronowicki JP, et al. Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. J Hepatol. 2015;62(2):492–493. doi:10.1016/j.jhep.2014.08.035
   PubMed Web of Science ®Google Scholar
• Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an optimal staging system for intermediate-stage hepatocellular carcinoma: comparison of 9 currently used prognostic models. J Hepatocell Carcinoma. 2021;8:253–261. doi:10.2147/JHC.S305581
   PubMed Web of Science ®Google Scholar
• Moctezuma-Velazquez C, Montano-Loza AJ, Meza-Junco J, et al. Selective internal radiation therapy for hepatocellular carcinoma across the Barcelona clinic liver cancer stages. Dig Dis Sci. 2021;66(3):899–911. doi:10.1007/s10620-020-06245-y
   PubMed Web of Science ®Google Scholar
• Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73(1):121–129. doi:10.1016/j.jhep.2020.03.005
   PubMed Web of Science ®Google Scholar
• Labgaa I, Taffe P, Martin D, et al. Comparison of partial hepatectomy and transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer. 2020;9(2):138–147. doi:10.1159/000505093
   PubMed Web of Science ®Google Scholar
• Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190. doi:10.1002/hep.27443
   PubMed Web of Science ®Google Scholar
• Giannini EG, Moscatelli A, Pellegatta G, et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol. 2016;111(1):70–77. doi:10.1038/ajg.2015.389
   PubMed Web of Science ®Google Scholar
• Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37(6):481–491. doi:10.1007/s12664-018-0915-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(03):329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol. 2016;22(1):7–17. doi:10.3350/cmh.2016.22.1.7
   PubMed Web of Science ®Google Scholar
• Galun D, Bogdanovic A, Zivanovic M, Zuvela M. Short- and long-term outcomes after hepatectomy in elderly patients with hepatocellular carcinoma: an analysis of 229 cases from a developing country. J Hepatocell Carcinoma. 2021;8:155–165.
   PubMed Web of Science ®Google Scholar
• Kaibori M, Yoshii K, Yokota I, et al. Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg. 2019;269(4):692–699. doi:10.1097/SLA.0000000000002526
   PubMed Web of Science ®Google Scholar
• Zhang XP, Zhou TF, Wang ZH, et al. Association of preoperative hypercoagulability with poor prognosis in hepatocellular carcinoma patients with microvascular invasion after liver resection: a multicenter study. Ann Surg Oncol. 2019;26(12):4117–4125. doi:10.1245/s10434-019-07504-7
   PubMed Web of Science ®Google Scholar
• Wang L, Li Q, Zhang J, et al. A novel prognostic scoring model based on albumin and gamma-glutamyltransferase for hepatocellular carcinoma prognosis. Cancer Manag Res. 2019;11:10685–10694. doi:10.2147/CMAR.S232073
   PubMed Web of Science ®Google Scholar
• Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci. 2014;15(3):5163–5174. doi:10.3390/ijms15035163
   PubMed Web of Science ®Google Scholar
• Li S, Xu W, Liao M, et al. The significance of gamma-glutamyl transpeptidase to lymphocyte count ratio in the early postoperative recurrence monitoring and prognosis prediction of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:23–33. doi:10.2147/JHC.S286213
   PubMed Web of Science ®Google Scholar
• Xia J, Song P, Sun Z, et al. Advances of diagnostic and mechanistic studies of gamma-glutamyl transpeptidase in hepatocellular carcinoma. Drug Discov Ther. 2016;10(4):181–187. doi:10.5582/ddt.2016.01052
   PubMedGoogle Scholar